Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM34FEA)

• Drug Name: ATA2431 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Preclinical	[1]

• Cross-matching ID: TTD Drug ID: DM34FEA

Molecule-Related Drug Atlas

Drug(s) Targeting B-cell receptor CD22 (CD22)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moxetumomab pasudotox	DMN63DZ	Hairy cell leukaemia	2A82.2	Approved	[2]
Inotuzumab ozogamicin	DMAC130	Acute lymphoblastic leukaemia	2A85	Approved	[3]
OspA lipoprotein	DMF5ZB3	Lyme disease	1C1G	Approved	[4]
Epratuzumab	DMI1ZXV	Acute lymphoblastic leukaemia	2A85	Phase 3	[5]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[6]
BL-22	DM8R71T	Acute lymphoblastic leukaemia	2A85	Phase 2	[7]
CAR-T cells targeting CD22	DM6XN4C	Non-hodgkin lymphoma	2B33.5	Phase 2	[8]
AUTO3	DMC5NSO	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[9]
CART-19/22	DMX0R1E	leukaemia	2A60-2B33	Phase 1/2	[10]
CD19 and CD22 CAR-T Cells	DM581CS	B-cell lymphoma	2A86	Phase 1/2	[11]

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[12]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[14]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[15]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[16]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[17]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[18]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[19]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[20]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[21]

Drug(s) Targeting Leukocyte surface antigen Leu-16 (CD20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[22]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[23]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[24]
Ibritumomab	DMG594T	Non-hodgkin lymphoma	2B33.5	Approved	[25]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[26]
Ublituximab	DMHTY9W	Multiple sclerosis	8A40	Approved	[27]
Tositumomab	DMMYZ3D	Non-hodgkin lymphoma	2B33.5	Approved	[25]
Obinutuzumab	DM3BVAE	Chronic lymphocytic leukaemia	2A82.0	Approved	[28]
Ofatumumab	DM295PR	Chronic lymphocytic leukaemia	2A82.0	Approved	[29]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[30]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell receptor CD22 (CD22)	TTM6QSK	CD22_HUMAN	Not Available	[1]
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Not Available	[1]
Leukocyte surface antigen Leu-16 (CD20)	TTUE541	CD20_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Atara Biotherapeutics.
• [2] Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
• [3] Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
• [4] Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
• [5] New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
• [6] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [7] Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
• [8] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [9] ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
• [10] ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
• [11] ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
• [12] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [13] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [18] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [19] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [20] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [21] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [24] Clinical pipeline report, company report or official report of Genmab.
• [25] Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23.
• [26] [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8.
• [27] The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628).
• [29] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [30] Clinical pipeline report, company report or official report of Genentech (2009).